Phase 1 Study of Ixazomib, an Investigational Proteasome Inhibitor, in Advanced Non-Hematologic Malignancies

Investigational New Drugs - Netherlands
doi 10.1007/s10637-015-0230-x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

A Phase I Study to Assess the Mass Balance, Excretion, and Pharmacokinetics of [14c]-Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors

Investigational New Drugs
OncologyPharmacology
2017English

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora a Kinase Inhibitor, in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2012English

Phase I Study of GSK461364, a Specific and Competitive Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Malignancies

Clinical Cancer Research
Cancer ResearchOncology
2011English

Hematologic Malignancies

Oncologist
Cancer ResearchMedicineOncology
1999English

Ih2 Inhibition Enhances Proteasome Inhibitor Responsiveness in Hematological Malignancies

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Phase I Study of S-Trans, Trans-Farnesylthiosalicylic Acid (Salirasib), a Novel Oral RAS Inhibitor in Patients With Refractory Hematologic Malignancies

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2015English

Preclinical Evaluation of Antitumor Activity of the Proteasome Inhibitor MLN2238 (Ixazomib) in Hepatocellular Carcinoma Cells

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2018English

A Phase 1 Study of Cetuximab and Lapatinib in Patients With Advanced Solid Tumor Malignancies

Cancer
Cancer ResearchOncology
2015English

A Phase I Study of Indoximod in Patients With Advanced Malignancies

Oncotarget
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy